Alpha-Gal Syndrome Leukopak

Alpha-Gal Syndrome Leukopak for Allergy and Type 2 Immunity Research

LeukoCore Alpha-Gal Syndrome Leukopak biospecimens are collected from IRB-consented donors clinically diagnosed with alpha-gal syndrome (AGS) through IRB-approved apheresis procedures. Each leukopak contains large quantities of peripheral blood mononuclear cells, processed and shipped within 24 hours of collection, making it suitable for high-cell-demand allergy immunology and drug development work.

Alpha-Gal Sensitisation and Why a Leukopak

Alpha-gal syndrome is an IgE-mediated, type 2 allergic condition. It is not autoimmune. Sensitisation is to a carbohydrate rather than a protein, which makes it mechanistically distinct from most food allergies.

  • The target allergen is galactose-alpha-1,3-galactose (alpha-gal), an oligosaccharide present in non-primate mammalian tissue but absent in humans
  • Sensitisation follows tick bites, with specific IgE to alpha-gal developing after exposure; in the United States the lone star tick is the principal implicated species
  • Subsequent ingestion of mammalian meat produces a characteristically delayed allergic reaction, typically hours after eating, reflecting the time needed for lipid-associated alpha-gal to be processed and presented
  • Because the epitope is a glycan, cross-reactivity extends to alpha-gal-bearing biologics and gelatin-containing products, which is directly relevant to biologic drug safety research
  • Alpha-gal-specific IgE, effector cell activation via FcepsilonRI on basophils and mast cells, and type 2 T cell help are the mechanistic axes under study
  • A leukopak provides the cell numbers needed for basophil activation testing, antigen-specific T cell work, cell sorting into rare subsets, and multi-omic profiling from a single donor

Donor Stratification Available

  • Alpha-gal-specific IgE level band where available
  • Reaction severity, including history of anaphylaxis versus cutaneous-only reactions
  • Documented tick-bite exposure history
  • Time since diagnosis and current dietary avoidance status
  • Comorbid atopic conditions such as asthma, allergic rhinitis, or other food allergy
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO) human leukopaks
  • Clinically confirmed AGS donors
  • High cell yield for large-scale studies
  • Processed and shipped within 24 hours of collection
  • Fresh or cryopreserved options available
  • IRB-approved and ethically sourced
  • Infectious disease testing
  • HLA-A typing
  • Screen donors with LeukoLot™

De-identified Donor Data

  • Verified Alpha-Gal Syndrome (AGS) diagnosis from healthcare providers
  • Donor demographics: age, sex assigned at birth, race/ethnicity
  • Self-reported medication history and allergies
  • Relevant clinical data including AGS severity (if available)

Applications

  • Basophil activation testing with alpha-gal-bearing antigens
  • Antigen-specific T cell identification and expansion
  • Immune cell characterisation and deep immunophenotyping in AGS
  • Cytokine profiling of type 2 responses following ex vivo stimulation
  • Mast cell and effector cell precursor isolation for functional assays
  • Biologic drug hypersensitivity and glycan cross-reactivity research
  • Multi-omics studies including single-cell sequencing
  • Therapeutic development, tolerance induction and screening

Other Alpha-Gal Syndrome Specimen Types

Compliance and Quality Assurance

  • Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
  • HIPAA-compliant handling of donor information
  • Rigorous donor screening and documentation

Ordering & Customization

Alpha-Gal Syndrome Leukopak samples are available fresh or cryopreserved. For pricing, availability, or a different condition, visit our human leukopak page to browse other disease-state options and live stock status. For international shipping or regulatory documentation, please contact learnmore@sanguinebio.com to confirm regional compliance and shipping availability.

Protocols & Documentation

  • Leukopak Cryopreservation

    Standard operating procedure for cryopreserving leukopak units with controlled freezing and post-thaw viability targets.

    Download
  • Leukopak Thawing

    Validated thawing workflow for cryopreserved leukopaks to maximize recovery while maintaining sterility and chain of custody.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Leukopak

Frequently Asked Questions

Showing 1–12 of 24 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Leukopak cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information